Drug Trial Radar · NCT00003958
Combination Chemotherapy in Treating Patients With Previously Untreated Rhabdomyosarcoma
Last checked: Nov 20, 2026Latest source record: Jun 17, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
702
Actual
Start
Sep 2002
Primary completion
Oct 2007
Sponsor
- Lead sponsor
- Children's Oncology GroupResearch network
- Sponsor type
- Research network
- Collaborators
- National Cancer Institute (NCI)
- First posted
- Jan 27, 2003
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, up to 49 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This randomized phase III trial is comparing two different combination chemotherapy regimens to see how well each works in treating patients with previously untreated rhabdomyosarcoma or sarcoma. Drugs used in chemotherapy, such as dactinomycin, cyclophosphamide, vincristine, and topotecan, use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which combination chemotherapy regimen is more effective in treating rhabdomyosarcoma.
Conditions
- Adult Malignant Mesenchymoma
- Adult Rhabdomyosarcoma
- Alveolar Childhood Rhabdomyosarcoma
- Childhood Malignant Mesenchymoma
- Embryonal Childhood Rhabdomyosarcoma
- Embryonal-botryoid Childhood Rhabdomyosarcoma
- Nonmetastatic Childhood Soft Tissue Sarcoma
- Previously Untreated Childhood Rhabdomyosarcoma
- Stage I Adult Soft Tissue Sarcoma
- Stage II Adult Soft Tissue Sarcoma
- Stage III Adult Soft Tissue Sarcoma
Interventions
dactinomycinBiological
Given IV
vincristine sulfateDrug
Given IV
cyclophosphamideDrug
Given IV
therapeutic conventional surgeryProcedure
Undergo surgery
radiation therapyRadiation
Undergo radiotherapy
topotecan hydrochlorideDrug
Given IV
filgrastimBiological
Given SC
sargramostimBiological
Given SC
laboratory biomarker analysisOther
Correlative studies
Primary outcomes
What the sponsor says the trial is designed to measure.
- Long-term failure-free survival (FFS) between the two treatment groupsTime frame: Up to 5 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Children's Oncology Group
Arcadia, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.